Diplomat Pharmacy (NYSE:DPLO) issued an update on its FY19 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of ($2.69-2.55) for the period, compared to the Thomson Reuters consensus estimate of ($0.54). The company issued revenue guidance of $4.7-5.0 billion, compared to the consensus revenue estimate of $4.91 billion.Diplomat Pharmacy also updated its FY 2019 guidance to $-2.69–2.55 EPS.
NYSE DPLO traded up $0.40 on Friday, reaching $5.72. The stock had a trading volume of 2,792,765 shares, compared to its average volume of 603,767. The firm has a 50 day simple moving average of $5.57. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.00 and a quick ratio of 0.66. Diplomat Pharmacy has a 1 year low of $4.17 and a 1 year high of $21.48. The company has a market capitalization of $382.53 million, a P/E ratio of 28.60 and a beta of 1.06.
Diplomat Pharmacy (NYSE:DPLO) last issued its earnings results on Friday, August 9th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). Diplomat Pharmacy had a negative net margin of 5.85% and a positive return on equity of 1.38%. The firm had revenue of $1.29 billion during the quarter, compared to analysts’ expectations of $1.23 billion. During the same quarter last year, the firm earned ($0.05) EPS. The business’s revenue for the quarter was down 9.1% compared to the same quarter last year. On average, research analysts forecast that Diplomat Pharmacy will post -0.55 EPS for the current year.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.
Featured Story: Price-Sales Ratio
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.